James R. Howe
YOU?
Author Swipe
View article: Control of innate olfactory valence by segregated cortical amygdala circuits
Control of innate olfactory valence by segregated cortical amygdala circuits Open
Animals exhibit innate behaviors that are stereotyped responses to specific evolutionarily relevant stimuli in the absence of prior learning or experience. These behaviors can be reduced to an axis of valence, whereby specific odors evoke …
View article: Control of innate olfactory valence by segregated cortical amygdala circuits
Control of innate olfactory valence by segregated cortical amygdala circuits Open
Animals exhibit innate behaviors that are stereotyped responses to specific evolutionarily relevant stimuli in the absence of prior learning or experience. These behaviors can be reduced to an axis of valence, whereby specific odors evoke …
View article: Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies
Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies Open
Neuroendocrine neoplasms (NENs) are rare cancers originating in various organs and are further classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Commonly used drugs s…
View article: Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( <scp>ENETS CoE</scp> )—An <scp>ENETS MEN1</scp> task force questionnaire study
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( <span>ENETS CoE</span> )—An <span>ENETS MEN1</span> task force questionnaire study Open
Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation in practices. Evidence on…
View article: Functional Copy-Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors
Functional Copy-Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors Open
Functional copy-number alterations (fCNAs) are DNA copy-number changes with concordant differential gene expression. These are less likely to be bystander genetic lesions and could serve as robust and reproducible tumor biomarkers. To iden…
View article: Functional Copy Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors
Functional Copy Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors Open
Functional copy number alterations (fCNAs) are DNA copy number changes with concordant differential gene expression. These are less likely to be bystander genetic lesions and could serve as robust and reproducible tumor biomarkers. To iden…
View article: Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor Open
Context Pancreatic neuroendocrine tumors (PNETs) exhibit a wide range of behavior from localized disease to aggressive metastasis. A comprehensive transcriptomic profile capable of differentiating between these phenotypes remains elusive. …
View article: Divergent Learning-Related Transcriptional States of Cortical Glutamatergic Neurons
Divergent Learning-Related Transcriptional States of Cortical Glutamatergic Neurons Open
Experience-dependent gene expression reshapes neural circuits, permitting the learning of knowledge and skills. Most learning involves repetitive experiences during which neurons undergo multiple stages of functional and structural plastic…
View article: Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of Neuroendocrine Tumors with Machine Learning
Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of Neuroendocrine Tumors with Machine Learning Open
Determining neuroendocrine tumor (NET) primary sites is pivotal for patient care as pancreatic NETs (pNETs) and small bowel NETs (sbNETs) have distinct treatment approaches. The diagnostic power and prioritization of fluorescence in situ h…
View article: Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers
Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers Open
Intermediate to high-grade lung neuroendocrine tumors (NETs; i.e., atypical carcinoid tumors) and neuroendocrine carcinomas (NECs) are currently difficult to cure. These tumors were found to express the CXCR4 G-protein coupled receptor tha…
View article: Multiomic sequencing of paired primary and metastatic small bowel carcinoids
Multiomic sequencing of paired primary and metastatic small bowel carcinoids Open
Background: Small intestine neuroendocrine tumors (SI-NETs), also called “carcinoids,” are insidious tumors that are often metastatic when diagnosed. Limited studies on the mutational landscape of small bowel carcinoids indicate that these…
View article: Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients
Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients Open
SCAN, an online survey, measured access to diagnosis, treatments and monitoring of neuroendocrine tumor (NET) patients globally. Between September and November 2019, NET patients and healthcare professionals (HCPs) completed an online, sem…
View article: Multiomic sequencing of paired primary and metastatic small bowel carcinoids
Multiomic sequencing of paired primary and metastatic small bowel carcinoids Open
Background: Small bowel carcinoids are insidious tumors that are often metastatic when diagnosed. Limited mutation landscape studies of carcinoids indicate that these tumors have a relatively low mutational burden. The development of targe…
View article: Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth<i>in vivo</i>
Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth<i>in vivo</i> Open
Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. SBNETs express high levels of tryptophan hydroxylase 1 (Tph1), a key enzyme in serotonin biosynthesis…
View article: Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 5
View article: Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 5
View article: Supplementary table 4 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 4 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 4
View article: Supplementary table 2 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 2 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 2
View article: Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 1
View article: Data from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Data from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Purpose:Pancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past…
View article: Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 1
View article: Data from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Data from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Purpose:Pancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past…
View article: Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 6
View article: Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors Open
Supplementary table 6